CG Oncology, Inc. (CGON)
| Market Cap | 5.90B +179.3% |
| Revenue (ttm) | 5.07M +666.0% |
| Net Income | -186.75M |
| EPS | -2.35 |
| Shares Out | 88.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,181,114 |
| Open | 69.20 |
| Previous Close | 69.54 |
| Day's Range | 66.47 - 70.00 |
| 52-Week Range | 23.38 - 75.50 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 79.36 (+18.57%) |
| Earnings Date | May 8, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $79.36, which is an increase of 18.57% from the latest price.
News
CG Oncology reports first results from CORE-008 Cohort CX
CG Oncology (CGON) announced first results from CORE-008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent ...
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
CG Oncology price target raised to $82 from $77 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $82 from $77 and keeps a Buy rating on the shares. The firm notes that following its recent discussions…
CG Oncology Transcript: Bank of America Global Healthcare Conference 2026
Healthpeak completed the Janus carve-out and IPO, unlocking value and positioning both REITs for growth. Outpatient medical and lab real estate remain core, with strong demand, strategic acquisitions, and robust cash flow. Janus is set for rapid expansion, leveraging favorable senior housing trends.
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
CG Oncology price target raised to $81 from $79 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $81 from $79 and keeps an Outperform rating on the shares after its Q1 results and the firm’s…
CG Oncology price target raised to $80 from $77 at Wedbush
Wedbush raised the firm’s price target on CG Oncology (CGON) to $80 from $77 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
CG Oncology price target raised to $96 from $91 at JPMorgan
JPMorgan raised the firm’s price target on CG Oncology (CGON) to $96 from $91 and keeps an Overweight rating on the shares.
CG Oncology price target lowered to $83 from $84 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on CG Oncology (CGON) to $83 from $84 and keeps a Buy rating on the shares. The firm remains positive on…
CG Oncology reports Q1 EPS (71c), consensus (54c)
Reports Q1 revenue $1.08M, consensus $453,030. “We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and w...
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
CG Oncology to Present at Upcoming Investor Conferences in May
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, ...
CG Oncology price target raised to $79 from $73 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $79 from $73 and keeps an Outperform rating on the shares. One of the most complex catalysts in…
JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
JPMorgan raised the firm’s price target on CG Oncology (CGON) to $91 from $65 and keeps an Overweight rating on the shares. JPMorgan also placed CG on “Positive Catalyst Watch”…
CG Oncology price target raised to $84 from $72 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on CG Oncology (CGON) to $84 from $72 and keeps a Buy rating on the shares. Shares have run up 62%…
JPMorgan healthcare analysts hold an analyst/industry conference call
Healthcare Analysts discuss Non-muscle invasive bladder cancer (NMIBC) (relevant companies CG Oncology (CGON) and Protara Therapeutics (TARA) on an Analyst/Industry conference call to be held on April...
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on CG Oncology (CGON) to $100 from $80 and keeps a Buy rating on the shares as part of a…
CG Oncology price target raised to $90 from $60 at UBS
UBS raised the firm’s price target on CG Oncology (CGON) to $90 from $60 and keeps a Buy rating on the shares. CG Oncology’s Phase 3 PIVOT-006 trial is evaluating…
CG Oncology price target raised to $72 from $65 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on CG Oncology (CGON) to $72 from $65 and keeps a Buy rating on the shares. The firm views today’s data…
CG Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Credo demonstrates strong efficacy and durability in multiple bladder cancer settings, with a 75.5% CR rate in BOND-003 and promising adjuvant and combination data. Regulatory filings are underway, with commercial launch preparations targeting a concentrated market and leveraging a robust team.
CG Oncology price target raised to $80 from $75 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on CG Oncology (CGON) to $80 from $75 and keeps a Buy rating on the shares. CG Oncology is progressing toward a biologics…
CG Oncology reports FY25 EPS ($2.08), consensus (58c)
Reports revenue $4.04M, consensus $515,180. “In the coming months, we look forward to sharing topline data from PIVOT-006, the first randomized registrational trial to evaluate an investigational ther...
CG Oncology sees cash runway into 1H29
Net proceeds of approximately $188.0 million was raised from a total of 3,623,101 shares sold in January 2026 through the Company’s ATM facility, resulting in a cash, cash equivalents, and…
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updat...
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating ...